$TMS

Teamshares Inc (TMS): Results of Operations and Financial Condition

Teamshares Inc (TMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 teamshares-20260630xq2earn.htm EX-99.1 Document Teamshares Reports 2Q 2026 Results and Reaffirms 2026 Outlook New York, NY – August 14, 2026 – Teamshares (NASDAQ:TMS, the “Company”), a tech-enabled acquiror of high-quality SMEs, announced financial results for the secon

Original reporting
Published Aug 14, 2026, 11:10 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 11:20 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$TMS
Bullish
medium confidence
Mentioned
$TMS
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$TMSBullishMed
01

Why it matters

The 8-K provides a full set of quarterly operating metrics, reiterates 2026 guidance, and updates the acquisition pipeline and financing plan, which together affect valuation drivers like growth rate, margin/EBITDA trajectory, and capital availability.

02

Market read

Traders can reassess near-term deal execution probability and capital structure risk using the disclosed EBITDA growth, LOI pipeline ($30M annual EBITDA), and proposed warehouse facility plus refinancing evaluation.

03

What to watch

Debt deleveraging is mentioned, but the refinancing process is still subject to definitive documentation, which could affect cost of capital and deal timing.

Relevance 7/10Novelty 8/10Timing: pre-market today, filed 8:10 a.m. ET with 8:30 a.m. ET conference call

Background

Teamshares is a tech-enabled acquiror of SME businesses and began trading on Nasdaq on June 23, 2026 after a significant equity raise.

Company-level read

Ticker impact

$TMSBullishMedium confidence
Context

Teamshares reported 2Q 2026 results and reaffirmed 2026 Pro Forma Adjusted EBITDA guidance of $60M, plus LOIs for 10 acquisitions.

Expected impact

Moderately positive bias, with volatility likely around financing and acquisition closing assumptions.

Evidence & confidence

The filing discloses multiple decision-relevant items: revenue, net income, adjusted EBITDA, reaffirmed guidance, LOI pipeline size ($30M annual EBITDA), and proposed senior secured warehouse facility plus debt refinancing evaluation.

Market effects

Adds datapoints for programmatic acquirer models, highlighting reliance on acquisition financing and warehouse facilities to fund deal flow.

No clear regional spillover beyond US small-cap M&A and capital markets sentiment.

Limited, as the disclosure is company-specific and US-listed.

Counterpoint

The LOIs are non-binding and the warehouse facility is only a proposed term sheet, so the market may discount pipeline EBITDA until definitive agreements and financing close.

Key entities

  • Teamshares Inc

    Reports 2Q 2026 results, reaffirms 2026 Pro Forma Adjusted EBITDA guidance, and updates acquisition LOIs and financing plans.

  • Live Oak Acquisition Corp. V

    Referenced as part of the business combination that provided gross proceeds and enabled debt repayment.

  • Teamshares CEO Michael Brown

    Quoted on momentum from Nasdaq listing and equity raise and the acquisition model.

  • Teamshares President Alex Eu

    Quoted on the acquisition funnel and scaling of the operating model.

Related articles

$NMRAMed

Neumora Therapeutics, Inc. (NMRA): Results of Operations and Financial Condition

Neumora Therapeutics, Inc. (NMRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 nmra-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by

$TVRDMed

Tvardi Therapeutics, Inc. (TVRD): Results of Operations and Financial Condition

Tvardi Therapeutics, Inc. (TVRD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2623143d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolera

$VSECMed

VSE (VSEC) Q2 2026 Earnings Call Transcript

VSE Corp (VSEC) Q2 2026 earnings call said it delivered record revenue and profitability. Revenue rose to $449 million, up 65% YoY, with 14% organic growth. Adjusted EBITDA was $86 million, up 98% YoY, and margin reached a record 19.2%. VSE said it closed the PAG deal May 5 (~$2B) and NorthStar on April 1, and raised full-year revenue and margin guidance.

$RELYMedAI 8/10

Remitly (RELY) Q2 2026 Earnings Call Transcript

Remitly (RELY) held its Q2 2026 earnings call, reporting record revenue and record adjusted EBITDA, both above the high end of guidance, and over 10 million quarterly active users. It said it added 5 countries to its payout network, nearly 70% of funded transfers delivered in under 20 seconds, and is a founding member of OpenUSD. It also discussed new licenses and product launches including a stablecoin wallet and Global Card.

$ORAMedAI 8/10

Ormat (ORA) Q2 2026 Earnings Call Transcript

Ormat (ORA) reported Q2 2026 results. Revenue rose 10.6% to $258.8M, gross profit increased 20.8% to $68.7M, and adjusted EBITDA grew 6.9% to $143.9M. Energy storage revenue nearly tripled to $42.8M. Ormat raised full-year revenue and adjusted EBITDA guidance, and declared a $0.12 quarterly dividend.